Evidence map›Paper›PMID 25661435›Full record

ArticleThe spine journal : official journal of the North American Spine Society2015

Intact glycosaminoglycans from intervertebral disc-derived notochordal cell-conditioned media inhibit neurite growth while maintaining neuronal cell viability.

Devina Purmessur, Marisa C Cornejo, Samuel K Cho, Peter J Roughley, Robert J Linhardt, Andrew C Hecht, James C Iatridis

Open access · greenAbstract read
In one paragraph

Article in The spine journal : official journal of the North American Spine Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Frontiers in pain research (Lausanne, Switzerland) · 2022
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Notochordal cell matrix: An inhibitor of neurite and blood vessel growth?Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Devina PurmessurLeni & Peter W. May Department of Orthopedics, Icahn School of Medicine at Mount Sinai, One Gustave L.levy place, box 1188 New York, NY 10029, USA.
Marisa C CornejoLeni & Peter W. May Department of Orthopedics, Icahn School of Medicine at Mount Sinai, One Gustave L.levy place, box 1188 New York, NY 10029, USA.
Samuel K ChoLeni & Peter W. May Department of Orthopedics, Icahn School of Medicine at Mount Sinai, One Gustave L.levy place, box 1188 New York, NY 10029, USA.
Peter J RoughleyGenetics Unit, Shriners Hospital for Children, 1529 Cedar Avenue Montreal, Quebec H3G 1A6, Canada.
Robert J LinhardtBiocatalysis & Metabolic Engineering Department, Rensselaer Polytechnic Institute Biotech 4005, 110 8th St., Troy, NY, 12180, USA.
Andrew C HechtLeni & Peter W. May Department of Orthopedics, Icahn School of Medicine at Mount Sinai, One Gustave L.levy place, box 1188 New York, NY 10029, USA.
James C IatridisLeni & Peter W. May Department of Orthopedics, Icahn School of Medicine at Mount Sinai, One Gustave L.levy place, box 1188 New York, NY 10029, USA. Electronic address: james.iatridis@mssm.edu.
Icahn School of Medicine at Mount Sinai · USRensselaer Polytechnic Institute · USShriners Hospitals for Children - Erie · US

Funding

Model of Human Disc Regeneration in the spectrum of Degenerative Disc DiseaseR01AR057397 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI IATRIDIS, JAMES C. · 2011 to 2021
$5.1M
Notochordal Cell Derived Therapies for Painful Disc DegenerationR01AR064157 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI IATRIDIS, JAMES C. · 2013 to 2017
$2.7M
NIAMS NIH HHS R01 AR057397NIAMS NIH HHS R01 AR064157
6 · The paper itself

Abstract

background contextPainful human intervertebral discs (IVDs) exhibit nerve growth deep into the IVD. Current treatments for discogenic back pain do not address the underlying mechanisms propagating pain and are often highly invasive or only offer temporary symptom relief. The notochord produces factors during development that pattern the spine and inhibit the growth of dorsal root ganglion (DRG) axons into the IVD. We hypothesize that notochordal cell (NC)-conditioned medium (NCCM) includes soluble factors capable of inhibiting neurite growth and may represent a future therapeutic target. PURPOSE: To test if NCCM can inhibit neurite growth and determine if NC-derived glycosaminoglycans (GAGs) are necessary candidates for this inhibition. STUDY

designHuman neuroblastoma (SH-SY5Y) cells and rat DRG cells were treated with NCCM in two-dimensional culture in vitro, and digestion and mechanistic studies determined if specific GAGs were responsible for inhibitory effects.

methodsNotochordal cell-conditioned medium was generated from porcine nucleus pulposus tissue that was cultured in Dulbecco's modified eagle's medium for 4 days. A dose study was performed using SH-SY5Y cells that were seeded in basal medium for 24 hours and neurite outgrowth and cell viability were assessed after treatment with basal media or NCCM (10% and 100%) for 48 hours. Glycosaminoglycans from NCCM were characterized using multiple digestions and liquid chromatography mass spectroscopy (LC-MS). Neurite growth was assessed on both SH-SY5Y and DRG cells after treatment with NCCM with and without GAG digestion.

resultsNotochordal cell-conditioned medium significantly inhibited the neurite outgrowth from SH-SY5Y cells compared with basal controls without dose or cytotoxic effects; % of neurite expressing cells were 39.0±2.9%, 27.3±3.6%, and 30.2±2.7% and mean neurite length was 60.3±3.5, 50.8±2.4, 53.2±3.7 μm for basal, 10% NCCM, and 100% NCCM, respectively. Digestions and LC-MS determined that chondroitin-6-sulfate was the major GAG chain in NCCM. Neurite growth from SH-SY5Y and DRG cells was not inhibited when cells were treated with NCCM with digested chondroitin sulfate (CS).

conclusionsSoluble factors derived from NCCM were capable of inhibiting neurite outgrowth in multiple neural cell types without any negative effects on cell viability. Cleavage of GAGs via digestion was necessary to reverse the neurite inhibition capacity of NCCM. We conclude that intact GAGs such as CS secreted from NCs are potential candidates that could be useful to reduce neurite growth in painful IVDs.

Indexed as

AnimalsCell Line, TumorCells, CulturedCell SurvivalCulture Media, ConditionedGlycosaminoglycansHumansIntervertebral DiscMaleNeuritesNotochordRatsSwineCulture Media, ConditionedGlycosaminoglycansChondroitin sulfateGlycosaminoglycansIntervertebral discNeurite outgrowthNeuronal cellsNotochordal cells

Identifiers

PMID25661435
PMCPMC4416992
OpenAlexW2108459765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.